Stephen Willey, Stifel, focused on Niktimvo's sequential growth and biological rationale for IPF expansion. Closter cited strong persistency and account engagement, while Botwood emphasized ...

Calling itself a “disruptor” in the trillion-dollar insurance industry, Root, Inc. (NASDAQ:ROOT) stock is down 8.2% over the past week, and roughly 21% year-to-date, even as Reddit sentiment sits at ...

Last year was a big one for artificial intelligence (AI) stocks, with companies in the sector leading all three major benchmarks to gains. Though the momentum halted temporarily earlier this year, as ...

For the third quarter of 2025, the Aristotle Small/Mid Cap Equity Composite generated a total return of 2.57% net of fees. The largest detractor from relative performance was security selection in ...

Form 13Fs provide a roadmap that allow investors to see which stocks Wall Street's smartest money managers are purchasing and selling. Bill Ackman has dumped 85% of Pershing Square's stake in Chipotle ...

The MarketWatch News Department was not involved in the creation of this content. Vyome's offering is a first-of-its-kind in a broader $20B potential addressable ocular inflammation market VT-1908 ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Entrepreneurship for Impact challenge (e4i Challenge) that ran last Friday was one of the biggest events for entrepreneurs in East Africa. The challenge was an occasion to vet, recognise and award ...

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity Vyome’s offering is a first-of-its-kind in a broader $20B ...